Wren Laboratories has unveiled NETest 2.0, a revolutionary AI-enhanced liquid biopsy diagnostic tool, marking a significant advancement in neuroendocrine tumor (NET) detection and monitoring. The company has officially discontinued its predecessor, NETest 1.0, in favor of this more sophisticated testing platform.
Advanced Diagnostic Capabilities
The next-generation NETest 2.0 employs a refined 51-gene mRNA expression algorithm, delivering unprecedented accuracy in NET diagnostics. Clinical validation data demonstrates remarkable performance metrics, including greater than 95% sensitivity for NET detection and exceeding 90% accuracy in identifying progressive disease. The test's PPQ Score has shown exceptional ability to predict patient response to Peptide Receptor Radionuclide Therapy (PRRT), with a 98% positive predictive value and 93% negative predictive value.
Global Validation and Clinical Impact
Dr. Abdel Halim, PharmD, PhD, CEO/CSO of Wren Laboratories, emphasizes the test's significance: "NETest 2.0 represents a major leap forward in patient surveillance and therapeutic decision-making for individuals with NETs. By integrating advanced machine learning with extensive global validation, we're setting a new standard for non-invasive tumor monitoring."
The test's reliability has been confirmed through extensive validation studies across diverse patient populations in the United States, Europe, Latin America, Africa, and Asia, establishing its utility as a universal diagnostic tool.
Clinical Applications and Expert Perspectives
Dr. Vikas Prasad, MD, PhD, associate professor of radiology at Washington University School of Medicine's Mallinckrodt Institute of Radiology, highlights the test's practical applications: "NET patients, specifically being treated with radiopharmaceutical therapies and under active surveillance may profit from state-of-the-art biomarkers like NETest 2.0. Integration of the 51-gene mRNA expression-based biomarker with imaging biomarker has the potential to further improve NET patients care."
Laboratory Standards and Availability
NETest 2.0 operates under CLIA, CAP, and NYSDOH CLEP certification, ensuring high-quality standards in laboratory testing. Dr. Mark Kidd, Laboratory Director at Wren Laboratories, notes: "With NETest 2.0, we've significantly enhanced diagnostic precision, allowing for improved patient surveillance and better treatment outcomes."
The test is now available to patients, investigators, and biopharmaceutical companies seeking advanced NET diagnostics, representing a new chapter in precision medicine for neuroendocrine tumor management.
